Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer

Jounce is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine has the potential to discover novel biological insights to drive the development of new immunotherapy treatments with durable responses, extending and improving patients' quality of life.

Jounce News


Dr. James Allison of MD Anderson Cancer Center Awarded 2014 Szent-Györgyi Prize for Progress in Cancer Research

Read More > >


Jounce Co-Founder Dr. James Allison Wins Breakthrough Prize for Innovative Cancer Immunology Research

Read More > >


Third Rock Ventures Launches Jounce Therapeutics with $47 Million Series A to Transform Cancer Treatment

Read More > >